ABSTRACT
Over the last two decades, several large randomized clinical trials have demonstrated advantages
of low-molecular-weight heparin (LMWH) over unfractionated heparin (UFH) for the prevention
and treatment of thromboembolic events (TEs) in adults. These advantages include predictable
pharmacokinetics; subcutaneous administration; no need for, or minimal, monitoring; decreased
risk of heparin-induced thrombocytopenia; and decreased risk of osteoporosis.
